ד"ר אנג'לה רובן
קורות חיים
תחומי מחקר
Research topic: Glutamate excitotoxicity and blood-glutamate scavenging in acute and chronic diseases
Research methods: HPLC, intracranial mouse and rat tumor models, brain metastatic animal models, neurotrauma animal models, behaviora tests, immunohistochemistry, pharmacodynamics and pharmacokinetics analysis, biochemical analysis of liver enzymes activity in a blood sample.
Main projects in the lab include:
- Blood glutamate scavenging as a novel neuroprotective treatment in the neurotrauma.
- Role of blood liver enzyme and glutamate levels and the pathophysiology of neurodegenerative and malignant diseases.
- Blood glutamate scavenging in the prevention of brain tumor invasiveness.
Publications
Avissar, S, Matuzany-Ruban, A, Tzukert, K, Schreiber, G.: b-arrestin-1 levels are reduced in leukocytes of patients with depression and elevated by antidepressants in rat brain. Am. J. Psychiatry Vol. 161; pp.2066-72, 2004.
Matuzany-Ruban, A, Avissar, S, Schreiber, G.: Dynamics of beta-arrestin1 protein and mRNA levels elevation by antidepressant in mononuclear leukocytes of patients with depression. Affective dis. Vol. 88; pp. 307-312, 2005.
Matuzany-Ruban, A, Schreiber, G, Farkash, P, Avissar, S.: Phosducin-like protein levels in leukocytes of patients with major depression and in rat cortex: the effect of chronic treatment with antidepressants. Psychiatry Res. Vol. 141(3); pp. 287-94, 2006.
Zlotnik, A, Gurevich, B, Cherniavsky, E, Tkachov, S, Matuzani-Ruban, A, Leon, A., Shapira, Y. and Teichberg, V.: The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injure. Neurochem Res. Vol. 33(6); pp. 1044-50, 2008.
Marosi, M, Fuzik, J, Nagy, D, Rákos, G, Kis, Z, Vécsei, L, Toldi, J, Ruban-Matuzani, A, Teichberg, VI, Farkas, T.: Oxaloacetate restores the long-term potentiation impaired in rat hippocampus CA1 region by 2-vessel occlusion. Eur J Pharmacol. Vol. 604(1-3); pp. 51-7, 2009
Matuzany-Ruban, A, Golan, M, Miroshnik, N, Schreiber, G, Avissar, S.: Normalization of GRK2 protein and mRNA measures in patients with depression predict response to antidepressants. Int J Neuropsychopharmacol. Vol. 29; pp. 83-91, 2009.
Ruban, A, Berkutzki T, Cooper I, Mohar B. and Teichberg, Vivian, I.: Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted glioma. Invest New Drugs. Vol. 30(6); pp. 2226-35, 2012.
Pérez-Mato, M, Ramos-Cabrer, P, Sobrino T, Blanco, M, Ruban, A, Mirelman, D, Menendez, P, Castillo, J, Campos, F.: Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. Cell Death Dis. Vol. 9; 5:e992, 2014.
Ruban, A, Mohar, B, Jona, G, Teichberg, VI.: Blood glutamate scavenging as a novel neuroprotective treatment for paraoxon intoxication. J Cereb Blood Flow Metab. Vol. 34(2); pp. 1-7, 2014.
Schwartz-Arad, D, Ofec, R, Eliyahu, G, Ruban, A, Sterer, N.: Long Term Follow-Up of Dental Implants Placed in Autologous Onlay Bone Graft. Clin Implant Dent Rel Res. doi: 10.1111/cid.12288; 2014.
Ruban, A, Biton, I, Markovich, A. and Mirelman, D.: MRS of Brain Metabolite Levels Demonstrates the Ability of Scavenging of Excess Brain Glutamate to Protect against Nerve Agent Induced Seizures. Int. J. Mol. Sci. Vol. 16 (2); pp. 3226-36, 2015.
Ruban, A, Cohen-Kashi Malina K, Cooper I, Graubardt N, Babakin L, Jona G, and Teichberg V. Combined treatment of an ALS rat model with recombinant GOT1 and Oxaloacetic acid: a novel neuroprotective treatment. Neurodegen Dis. 2015.
Schwartz-Arad, D, Ofec, R, Eliyahu, G, Sterer, N, Ruban, A. Onlay Bone Graft augmentation for the Treatment of Maxillary Atrophy: Implants long term follow-up (up to 131 months). J Cosmetic Dentistry Vol. 31(3); pp 76-93, 2015.
Goldshmit A, Jona G, Schmuklerd E, Solomond S, Pinkas-Kramarskid R and Ruban A. Blood Glutamate Scavenger as a novel neuroprotective treatment in spinal cord injury. J Neurotrauma Mar 1. doi: 10.1089/neu.2017.5524, 2018.
Tsivion-Visbord H, Pretes N, Bikivski L, Goldshmit Y, Ruban A, Offen D. MSCs-Derived-EVs as Potential Protection Against Behavioral and Biochemical Deficits in a Phencyclidine Model of Schizophrenia. Biol Psychiatry Vol. 87(9); S195, 2020.
Ruban A, Daya N, Schneider A.L.C., Gottesman R, Selvin E, Coresh J, Lazo M, Koton S. Liver enzymes and risk of stroke: The Atherosclerosis Risk in Communities Study (ARIC). J Stroke August, 2020.
Amit-Aharon A, Ruban A, Dubovi I. Knowledge and information credibility evaluation strategies regarding COVID-19: A cross-sectional study. 2021 January-February; 69(1): 22–31.
Amit-Aharon A, Dubovi I, Ruban A. Quality of Life Res Differences in mental health and health-related quality of life between Israel and Italy public sample during COVID-19 quarantine. Quality of Life Research Jan 14: 1–10, 2021.
Goldshmit Y, Perelroizen R, Yakovchuk A, Banyas E, Mayo L, David S, Benbenishty A, Blinder P, Shalom M, Ruban A. Blood glutamate scavengers increase pro-apoptotic signaling and reduce metastatic melanoma growth in-vivo. Sci Rep. 2021 Jul 19;11(1):14644.
S Poleg, Emad Kיourieh, A Ruban, G Shapira, N Shomron, B Barak and Daniel Offen . Behavioral Aspects and Neurobiological Properties Underlying Medical Cannabis Treatment in Shank3 Mouse Model of Autism Spectrum Disorder. Transl Psychiatry 2021 Oct 13;11(1):524.
Goldshmit Y, Shalom M and Ruban A.Treatment with Pulsed Extremely Low Frequency Electromagnetic Field (PELF-EMF) Exhibit Anti-Inflammatory and Neuroprotective Effect in Compression Spinal Cord Injury Model Special Issue Spinal Cord Injury: From Mechanisms to Nanotherapeutic Approache. Biomedicines 2022;10(2):325.
